Bottom line
PRHSX vs ETHSX: the short answer
PRHSX (T. Rowe Price Health Sciences Fund, Inc.) and ETHSX (Eaton Vance Worldwide Health Sciences Fund) share a meaningful slice of their top holdings — about 64% by weight.
But PRHSX is far broader, holding 279 positions to 42 for ETHSX, so beyond the top names it adds exposure ETHSX doesn't have.
PRHSX is cheaper at 0.83% vs 1.18% — a difference of $35 a year per $10,000 invested.
Over five years, ETHSX returned +5.3% a year vs +4.2% for PRHSX (reporting dates differ).
ETHSX has a front-end sales load of up to 5.25%; the other does not.
Updated Nov 19, 2026
PRHSX vs ETHSX side by side
| PRHSX | ETHSX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | T. Rowe Price | Morgan Stanley |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.83% | 1.18% |
| Annual cost per $10k | $83 | $118 |
| 10-yr cost on $10k (prospectus) | $1,025 | $1,911 |
| Max front load | — | 5.25% |
| 12b-1 fee | — | 0.25% |
| 1-yr return | +17.7% | −1.9% |
| 5-yr return (annualized) | +4.2% | +5.3% |
| 10-yr return (annualized) | +9.1% | +6.4% |
| Best quarter | +23.5% | +14.2% |
| Worst quarter | −15.8% | −12.1% |
| Net assets (fund) | $11.9B | $757.9M |
| Number of holdings | 279 | 42 |
| Portfolio turnover | 62% | 3% |
| Returns as of | Dec 31, 2025 | Dec 31, 2024 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | PRHSX | ETHSX | Difference |
|---|---|---|---|
| 2024 | +1.8% | +3.5% | −1.7% |
| 2023 | +3.1% | +5.7% | −2.6% |
| 2022 | −12.2% | −9.4% | −2.8% |
| 2021 | +13.3% | +22.1% | −8.8% |
| 2020 | +30.1% | +13.0% | +17.1% |
| 2019 | +29.1% | +26.0% | +3.1% |
| 2018 | +1.2% | +6.0% | −4.8% |
| 2017 | +28.0% | +16.2% | +11.7% |
| 2016 | −10.4% | −14.9% | +4.5% |
Source: Fund prospectus bar charts
Holdings overlap
12 of PRHSX's top 25 holdings also appear in ETHSX's top 25.
| Holding | PRHSX | ETHSX |
|---|---|---|
| Eli Lilly & Co | 14.28% | 12.47% |
| Johnson & Johnson | 6.63% | 6.45% |
| Unitedhealth Group Inc | 5.99% | 5.49% |
| Abbvie Inc | 5.10% | 6.46% |
| Merck & Co. Inc. | 4.01% | 5.08% |
| Gilead Sciences Inc | 2.82% | 3.34% |
| Thermo Fisher Scientific Inc | 2.52% | 2.79% |
| Vertex Pharmaceuticals Inc | 2.28% | 3.38% |
| Bristol-myers Squibb Co | 2.11% | 4.25% |
| Abbott Laboratories | 1.89% | 1.65% |
| Intuitive Surgical Inc | 1.87% | 2.72% |
| Stryker Corp | 1.78% | 2.21% |
Source: SEC Form N-PORT
PRHSX top 10
- Eli Lilly & Co — 14.28%
- Johnson & Johnson — 6.63%
- Unitedhealth Group Inc — 5.99%
- Abbvie Inc — 5.10%
- Merck & Co. Inc. — 4.01%
- Gilead Sciences Inc — 2.82%
- Thermo Fisher Scientific Inc — 2.52%
- Vertex Pharmaceuticals Inc — 2.28%
- Bristol-myers Squibb Co — 2.11%
- Abbott Laboratories — 1.89%
ETHSX top 10
- Eli Lilly & Co — 12.47%
- AbbVie Inc — 6.46%
- Johnson & Johnson — 6.45%
- AstraZeneca PLC — 6.24%
- UnitedHealth Group Inc — 5.49%
- Roche Holding AG — 5.44%
- Merck & Co Inc — 5.08%
- Bristol-Myers Squibb Co — 4.25%
- Vertex Pharmaceuticals Inc — 3.38%
- Gilead Sciences Inc — 3.34%
FAQ
What is the difference between PRHSX and ETHSX?
Which is cheaper, PRHSX or ETHSX?
Should I own both PRHSX and ETHSX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.